Nasdaq · CIK 0001806952
LYEL Lyell Immunopharma, Inc.
Insider trading from SEC Form 4. Last filing 32 d ago. Close $8.71 on Oct 9, 2026, +2% from the 52-week low and -77% from the high.
Last 90 days
Net insider value
-$6,350
more sold than bought
Buys
0
$0 by 0 insiders
Sells
1
$6,350 by 1 insider
Insiders on file
11
with a Form 4 at this company
Price and insider trades, last year
LYELOct 9, 2026 · close 8.71
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Lyell Immunopharma, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | David Shook Chief Medical Officer sell | $6,350 500 shares | -2% | - | |
| 31Weak | Otis W Brawley director buy | $20k 35,640 shares | - | +11% from low-66% from high | |
| 31Weak | Richard Klausner director buy | $95k 158,000 shares | +23% | - |
Transactions
The last 18 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | David Shook Chief Medical Officer | SOpen-market sale Common Stock | -500 | $12.70 | $6,350 | 20,423 | 32 d ago |
| Sep 10, 2026 | Jarrad Mattieu Aguirre Chief Medical Officer | AGrant or award Option (right to buy)derivative | +47,500 | $0.00 | $0 | 47,500 | 32 d ago |
| Jun 9, 2025 | Mark Bachleda director | AGrant or award Option (right to buy)derivative | +13,000 | $0.00 | $0 | 13,000 | Jun 11, 2025 |
| Jun 9, 2025 | David Shook Chief Medical Officer | AGrant or award Common Stock | +21,900 | $0.00 | $0 | 21,900 | Jun 11, 2025 |
| Jun 9, 2025 | Mark A Meltz General Counsel | AGrant or award Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jun 11, 2025 |
| Jun 9, 2025 | David Shook Chief Medical Officer | AGrant or award Option (right to buy)derivative | +43,750 | $0.00 | $0 | 43,750 | Jun 11, 2025 |
| May 15, 2025 | William Jl Rieflin director | AGrant or award Option (right to buy)derivative | +130,000 | $0.00 | $0 | 130,000 | May 19, 2025 |
| May 15, 2025 | Elizabeth G Nabel director | AGrant or award Option (right to buy)derivative | +130,000 | $0.00 | $0 | 130,000 | May 19, 2025 |
| May 15, 2025 | Sumant Ramachandra director | AGrant or award Option (right to buy)derivative | +130,000 | $0.00 | $0 | 130,000 | May 19, 2025 |
| May 15, 2025 | Otis W Brawley director | AGrant or award Option (right to buy)derivative | +130,000 | $0.00 | $0 | 130,000 | May 19, 2025 |
| May 15, 2025 | Richard Klausner director | AGrant or award Option (right to buy)derivative | +130,000 | $0.00 | $0 | 130,000 | May 19, 2025 |
| May 15, 2025 | Cathy Friedman director | AGrant or award Option (right to buy)derivative | +130,000 | $0.00 | $0 | 130,000 | May 19, 2025 |
| Mar 31, 2025 | Otis W Brawley director | POpen-market purchase Common Stock | +35,640 | $0.56 | $20k | 35,640 | Apr 2, 2025 |
| Mar 14, 2025 | Richard Klausner director | POpen-market purchase Common Stockindirect: Grantor and Trustee | +158,000 | $0.60 | $95k | 843,365 | Mar 18, 2025 |
| Feb 10, 2025 | Stephen J. Hill Chief Operating Officer | AGrant or award Common Stock | +112,500 | $0.00 | $0 | 172,899 | Feb 26, 2025 |
| Feb 10, 2025 | Stephen J. Hill Chief Operating Officer | AGrant or award Option (right to buy)derivative | +450,000 | $0.00 | $0 | 450,000 | Feb 26, 2025 |
| Feb 10, 2025 | Stephen J. Hill Chief Operating Officer | AGrant or award Option (right to buy)derivative | +56,250 | $0.00 | $0 | 56,250 | Feb 26, 2025 |
| Oct 31, 2024 | Sumant Ramachandra director | AGrant or award Option (right to buy)derivative | +260,000 | $0.00 | $0 | 260,000 | Nov 1, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Jarrad Mattieu AguirreChief Medical Officer
- Otis W Brawleydirector
- Mark Bachledadirector
- Cathy Friedmandirector
- Stephen J. HillChief Operating Officer
- Richard Klausnerdirector
- Mark A MeltzGeneral Counsel
- Elizabeth G Nabeldirector
- William Jl Rieflindirector
- Sumant Ramachandradirector
- David ShookChief Medical Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.